Cell/Gene Tx channel feed

FDA's Pe­ter Marks over­rode re­view­ers’ call to re­ject Sarep­ta’s new Duchenne gene ther­a­py

Last year
FDA+

Sarep­ta's gene ther­a­py to be man­u­fac­tured at Catal­ent plant with 'op­er­a­tional chal­lenges' this spring

Last year
Manufacturing

CAR-T cell ther­a­py for myas­the­nia gravis shows promise in small study by Carte­sian Ther­a­peu­tics

Last year
R&D

Up­dat­ed: FDA ap­proves Sarep­ta’s Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py via ac­cel­er­at­ed path­way

Last year
Pharma
FDA+

Cor­rect­ed: Prime Med­i­cine part­ners with Ver­sant-backed biotech to de­vel­op safer stem cell trans­plants

Last year
Deals

Sarep­ta's gene ther­a­py for Duchenne ex­pect­ed to get FDA rul­ing to­day

Last year
FDA+

Por­tal In­no­va­tions to call Hous­ton its third home, with CAR-T start­up March Bio­sciences al­ready in the port­fo­lio

Last year
Financing
Startups

Ul­tragenyx opens new gene ther­a­py man­u­fac­tur­ing site in Mass­a­chu­setts

Last year
Manufacturing

Ar­cel­lx's cell ther­a­py is on hold af­ter pa­tient death in mul­ti­ple myelo­ma tri­al

Last year
R&D

Prime Med­i­cine con­sid­ers fo­cus on au­toim­mune dis­eases for CAR-T, CEO says

Last year
R&D

Syn­cona takes write-down on Swan­Bio as biotech halves work­force to fo­cus on one gene ther­a­py

Last year
Financing
Startups

Verve snags $60M from Lil­ly to tack­le Lp(a) with one-time gene edit­ing

Last year
Deals
Pharma

ProKid­ney to es­tab­lish cell ther­a­py man­u­fac­tur­ing site in North Car­oli­na

Last year
Manufacturing

Pa­tient death leads Seat­tle Chil­dren’s to pause study of 2sev­en­ty bio’s CAR-T cell ther­a­py 

Last year
R&D

Turn­stone Bi­o­log­ics turns to pub­lic in­vestors to fund TIL ther­a­pies in IPO fil­ing

Last year
Financing

En­cod­ed Ther­a­peu­tics, a well-fund­ed CNS gene ther­a­py mak­er, lays off 10% of staff 

Last year
People
Startups

Charles Riv­er to work with Cu­ri­gin on gene ther­a­py treat­ment

Last year
Pharma
Manufacturing

Xalud Ther­a­peu­tics pri­or­i­tizes gene ther­a­pies, with ALS now the fo­cus and os­teoarthri­tis on part­ner path 

Last year
People
Startups

Re­ju­ve­nate Bio shrinks staff, pipeline fo­cus as George Church spin­out eyes 2024 gene ther­a­py IND

Last year
People
Startups

Ex-Night­star, Gy­ro­scope and AGTC teams try again for next reti­nal gene ther­a­py with $120M for Bea­con Ther­a­peu­tics

Last year
Financing
Startups

Bris­tol My­ers cell ther­a­py man­u­fac­tur­ing site gets thumbs-up from FDA

Last year
Manufacturing

FDA wants more da­ta from Abeona Ther­a­peu­tics as it push­es for BLA

Last year
R&D
Manufacturing

FDA sets De­cem­ber ap­proval de­ci­sion for first CRISPR ther­a­py, with 94% of pa­tients free of sick­le cell crises

Last year
R&D
FDA+

As­traZeneca en­lists UK Treg biotech for type 1 di­a­betes, in­flam­ma­to­ry bow­el dis­ease deal fea­tur­ing $85M up­front

Last year
Deals
First page Previous page 17181920212223 Next page Last page
A service from the Financial Times